000046259 000__ 01108cam\a22003975i\4500
000046259 001__ 46259
000046259 003__ SzGeWIPO
000046259 005__ 20230511163900.0
000046259 006__ m\\\\eo\\d\\\\\\\\
000046259 007__ cr bn |||m|||a
000046259 008__ 220607s2020\\\\nyu\\\\\o\\\\\000\0\eng\d
000046259 035__ $$a(OCoLC)1335039219
000046259 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046259 041__ $$aeng
000046259 24500 $$aIntellectual property and equitable access to COVID-19 vaccines and therapeutics.
000046259 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2020
000046259 300__ $$a1 online resource
000046259 336__ $$atext$$2rdacontent
000046259 337__ $$acomputer$$2rdamedia
000046259 338__ $$aonline resource$$bcr$$2rdacarrier
000046259 4901_ $$aEuropean Intellectual Property Review,$$x0142-0461 ;$$vVolume 42, Issue 9
000046259 542__ $$fhttps://1.next.westlaw.com/Copyright
000046259 588__ $$aCrossref
000046259 590__ $$aPublished online: 2020
000046259 650_0 $$aIntellectual property.
000046259 650_4 $$aCOVID-19 pandemic
000046259 650_4 $$aTrade-Related Aspects of Intellectual Property (TRIPS)
000046259 650_0 $$aVaccines.
000046259 7001_ $$aOwoeye, Olasupo,$$eauthor.
000046259 7731_ $$tEuropean Intellectual Property Review
000046259 7731_ $$wEIPR
000046259 830_0 $$aEuropean Intellectual Property Review,$$vE.I.P.R. 2020, 42(9), 584-588
000046259 85641 $$uhttps://www.westlaw.com/Document/I7D6B672013F811EB8A6DF81E2F4F9E86/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046259 904__ $$aArticle
000046259 980__ $$aEIPR